| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rita C Carvalho, Daniela F Fukushiro, Daniel C Helfer, Donato Callegaro-Filho, Thaís F Trombin, Lineane H F Zanlorenci, Leandro Sanday, Regina H Silva, Roberto Frussa-Filh. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors. Addiction biology. vol 14. issue 3. 2009-09-24. PMID:19298320. |
long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine d2 receptors. |
2009-09-24 |
2023-08-12 |
mouse |
| Mariana Bendlin Calzavara, Wladimir Agostini Medrano, Raquel Levin, Sonia Regina Kameda, Monica Levy Andersen, Sergio Tufik, Regina Helena Silva, Roberto Frussa-Filho, Vanessa Costhek Abíli. Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia? Schizophrenia bulletin. vol 35. issue 4. 2009-08-06. PMID:18281713. |
pharmacological characterization consisted in the evaluation of the effects of the following drugs administered previously to the acquisition of the cfc: pentylenetetrazole (anxiogenic) and chlordiazepoxide (anxiolytic); methylphenidate and amphetamine (used for adhd); lamotrigine, carbamazepine, and valproic acid (mood stabilizers); haloperidol, ziprasidone, risperidone, amisulpride, and clozapine (neuroleptic drugs); metoclopramide and sch 23390 (dopamine antagonists without antipsychotic properties); and ketamine (a psychotomimmetic). |
2009-08-06 |
2023-08-12 |
rat |
| Camilo de la Fuente-Sandoval, Rafael Favila, Patricia Alvarado, Pablo León-Ortiz, Leonardo Díaz-Galvis, Carmen Amezcua, Erik García-Muñoz, Ariel Graff-Guerrer. [Glutamate increase in the associative striatum in schizophrenia: a longitudinal magnetic resonance spectroscopy preliminary study]. Gaceta medica de Mexico. vol 145. issue 2. 2009-07-30. PMID:19518017. |
to compare glutamate levels (glu) found in the dorsal-caudate nucleus (a dopamine rich region) and in the cerebellum (a low dopamine region) among: 1) schizophrenia patients undergoing an acute psychotic episode, 2) after receiving antidopaminergic treatment (risperidone), and 3) healthy controls. |
2009-07-30 |
2023-08-12 |
Not clear |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. European journal of pharmacology. vol 607. issue 1-3. 2009-07-07. PMID:19217900. |
in an effort to elucidate aripiprazole's pharmacological activity in relation to clinically relevant fluctuation of dopamine d(2) receptor reserves, we compared the properties of aripiprazole to other antipsychotics, quetiapine, clozapine, olanzapine, ziprasidone, risperidone and haloperidol, a dopamine d(2) receptor partial agonist, bifeprunox, dopamine d(3) receptor modulators, bp897 (n-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]naphthalene-2-carboxamide) and gr103691 (4'-acetyl-n-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]biphenyl-4-carboxamide), and a 5-ht(1a) partial agonist, buspirone using forskolin-stimulated camp accumulation in clonal chinese hamster ovary cell lines expressing low and high densities of human dopamine d(2s) receptors (hd(2s)-low and hd(2s)-high, respectively). |
2009-07-07 |
2023-08-12 |
human |
| Raúl de la Flor, Lee A Dawso. Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412). Neuropharmacology. vol 56. issue 2. 2009-07-01. PMID:18822303. |
as seen previously talnetant, produced a dose dependent increase in extracellular levels of both dopamine (da) and norepinephrine (ne) in both prefrontal cortex (pfc) and hippocampus in a similar manner to the atypical risperidone. |
2009-07-01 |
2023-08-12 |
Not clear |
| Chadi A Calarge, Vicki L Ellingrod, Laura Acion, Del D Miller, Jessica Moline, Michael J Tansey, Janet A Schlecht. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenetics and genomics. vol 19. issue 5. 2009-06-17. PMID:19339912. |
to investigate the association between hyperprolactinemia and variants of the dopamine d2 receptor (drd2) gene in children and adolescents in long-term treatment with risperidone. |
2009-06-17 |
2023-08-12 |
Not clear |
| Masashi Ikeda, Yoshio Yamanouchi, Yoko Kinoshita, Tsuyoshi Kitajima, Reiji Yoshimura, Shuji Hashimoto, Michael C O'Donovan, Jun Nakamura, Norio Ozaki, Nakao Iwat. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics. vol 9. issue 10. 2009-02-13. PMID:18855532. |
variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. |
2009-02-13 |
2023-08-12 |
Not clear |
| Zhu Li, Shikha Snigdha, Alex S Roseman, Jin Dai, Herbert Y Meltze. Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. European journal of pharmacology. vol 596. issue 1-3. 2009-01-12. PMID:18771666. |
the acetylcholine and dopamine efflux induced by xamomeline (10 mg/kg, s.c.) and sabcomeline (1 mg/kg, s.c.) were significantly blocked by the preferential muscarinic m(1) receptor antagonist telenzepine (3 mg/kg, s.c.), but significantly potentiated by the atypical antipsychotic drug risperidone (0.1 mg/kg, s.c.), which does not have much affinity for muscarinic receptor(s). |
2009-01-12 |
2023-08-12 |
rat |
| Mahendra Bishnoi, Kanwaljit Chopra, Shrinivas K Kulkarn. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 6. 2008-10-22. PMID:18554768. |
haloperidol significantly decreased the striatal dopamine levels whereas clozapine and risperidone did not. |
2008-10-22 |
2023-08-12 |
human |
| Hiroyuki Uchida, David C Mamo, Shitij Kapur, Alain Labelle, Chekkera Shammi, Erik J L Mannaert, Steve W Mann, Gary Remingto. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. The Journal of clinical psychiatry. vol 69. issue 8. 2008-10-15. PMID:18642974. |
monthly administration of long-acting injectable risperidone and striatal dopamine d2 receptor occupancy for the management of schizophrenia. |
2008-10-15 |
2023-08-12 |
Not clear |
| Hiroyuki Uchida, David C Mamo, Shitij Kapur, Alain Labelle, Chekkera Shammi, Erik J L Mannaert, Steve W Mann, Gary Remingto. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. The Journal of clinical psychiatry. vol 69. issue 8. 2008-10-15. PMID:18642974. |
the objective of this positron emission tomography (pet) study was to examine the striatal dopamine d(2) binding of long-acting risperidone administered intramuscularly once a month. |
2008-10-15 |
2023-08-12 |
Not clear |
| Christina Kurre Olsen, Lise Tøttrup Brennum, Mads Kreilgaar. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. European journal of pharmacology. vol 584. issue 2-3. 2008-07-01. PMID:18325493. |
we found the order of dopamine d2 receptor occupancy required to suppress conditioned avoidance response behaviour according to ec50 measurements to be sertindole (+dehydrosertindole)=dehydrosertindole=paliperidone (the metabolite of risperidone)=haloperidol=olanzapine>risperidone>>clozapine. |
2008-07-01 |
2023-08-12 |
human |
| Lesley J Scott, Sohita Dhillo. Spotlight on risperidone in irritability associated with autistic disorder in children and adolescents. CNS drugs. vol 22. issue 3. 2008-05-19. PMID:18278980. |
risperidone (risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine d(2) and serotonin 5-ht(2a) receptor antagonism. |
2008-05-19 |
2023-08-12 |
Not clear |
| Aiping Zhang, Qinghe Xing, Lei Wang, Jing Du, Lan Yu, Zhiguang Lin, Xingwang Li, Guoyin Feng, Lin H. Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. Pharmacogenomics. vol 8. issue 10. 2008-04-25. PMID:17979508. |
dopamine transporter polymorphisms and risperidone response in chinese schizophrenia patients: an association study. |
2008-04-25 |
2023-08-12 |
Not clear |
| Byungsu Kim, Eui Yul Choi, Chang Yoon Kim, Kyuyung Song, Yeon Ho Jo. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Human psychopharmacology. vol 23. issue 1. 2008-03-18. PMID:17924589. |
this study seeks to replicate previous results indicating that t102c in the serotonin 2a receptor (htr2a) and ser9gly in the dopamine d3 receptor (drd3) were associated with a risperidone response to acutely exacerbated schizophrenia, and to determine whether possession of these alleles predicts clinical improvement in a naturalistic setting. |
2008-03-18 |
2023-08-12 |
Not clear |
| Vera Bubenikova-Valesova, Ales Stuchlik, Jan Svoboda, Jan Bures, Karel Vale. Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task. Proceedings of the National Academy of Sciences of the United States of America. vol 105. issue 3. 2008-02-12. PMID:18195350. |
the aim of the present work was to establish the effect of the 5-ht2a/2c receptor antagonist ritanserin (2.5 or 5 mg/kg), the dopamine d2 antagonist haloperidol (0.1 or 1 mg/kg), and the atypical antipsychotic risperidone (0.1 mg/kg or 1 mg/kg), which is an antagonist of both 5-ht2a/2c and d2 receptors, on cognitive deficit induced by subchronic administration of dizocilpine (mk-801, 0.1 mg/kg). |
2008-02-12 |
2023-08-12 |
rat |
| Jiekun Xuan, Xinzhi Zhao, Guang He, Lan Yu, Lei Wang, Wei Tang, Xingwang Li, Niufan Gu, Guoyin Feng, Qinghe Xing, Lin H. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 2. 2008-02-06. PMID:17429404. |
effects of the dopamine d3 receptor (drd3) gene polymorphisms on risperidone response: a pharmacogenetic study. |
2008-02-06 |
2023-08-12 |
Not clear |
| Frans H L Awouters, Paul J Lew. Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen. Arzneimittel-Forschung. vol 57. issue 10. 2008-01-22. PMID:18074755. |
this research ultimately led to the discovery of risperidone (cas 106266-06-2) and paliperidone (cas 144598-75-4), compounds with inbuilt dopamine and serotonin antagonism. |
2008-01-22 |
2023-08-12 |
Not clear |
| Qinghe Xing, Xueqing Qian, Huafang Li, Shiming Wong, Shengnan Wu, Guoyin Feng, Shiwei Duan, Mingqing Xu, Rui Gao, Wei Qin, Jianjun Gao, Junwei Meng, Lin H. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. The international journal of neuropsychopharmacology. vol 10. issue 5. 2008-01-17. PMID:17105675. |
the relationship between the therapeutic response to risperidone and the dopamine d2 receptor polymorphism in chinese schizophrenia patients. |
2008-01-17 |
2023-08-12 |
Not clear |
| Zhu Li, Douglas W Bonhaus, Mei Huang, Adam J Prus, Jin Dai, Herbert Y Meltze. AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. European journal of pharmacology. vol 572. issue 2-3. 2008-01-14. PMID:17628522. |
in addition, pretreatment with the atypical antipsychotic drug risperidone (0.1 mg/kg, s.c.) potentiated ac260584 (1.0 mg/kg, s.c.)-induced acetylcholine and dopamine release in the medial prefrontal cortex. |
2008-01-14 |
2023-08-12 |
rat |